Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ocugen Inc (NQ: OCGN )

0.9086 -0.0136 (-1.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen Inc

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
33 34 Next >
Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2022
  
Via Benzinga
Where Ocugen Stands With Analysts
Analysts have provided the following ratings for Ocugen (NASDAQ:OCGN) within the last quarter: 
Via Benzinga
This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Outlook For Ocugen
Ocugen (NASDAQ:OCGN) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Ocugen will report an... 
Via Benzinga
Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years
Via Benzinga
Ocugen Diversifies Its Pipeline With New Cell Therapy Platform
Via Benzinga
OCGN Stock Falls Despite Positive FDA Update
Shares of the biotech company are falling despite news that the FDA has cleared it to resume clinical trials of its Covid-19 vaccine. 
Via InvestorPlace
Earnings Scheduled For August 5, 2022
Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million. 
Via Benzinga
FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial
Via Benzinga
The Top Reasons to Avoid the Ocugen Stock
WIth Ocugen, there’s nothing to get excited about here. Avoid the OCGN stock, as it heads significantly lower. 
Via InvestorPlace
Monitoring Board Gives Positive Recommendation On Ocugen's Eye Disease Gene Therapy Trial
Via Benzinga
Why Ocugen Shares Are Trading Higher Today
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
7 Stocks to Short Before July 2022
There are many highly overvalued publicly traded companies that will have trouble staying afloat, giving investors many stocks to short. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022
Via Benzinga
Why Is Ocugen (OCGN) Stock Down Today?
Shares of OCGN stock are trading lower after the FDA announced that it had placed a clinical hold on Covaxin. Here's what you should know. 
Via InvestorPlace
FDA Places Clinical Hold On Ocugen's Late-Stage COVID-19 Vaccine Trial
The  
Via Benzinga
Here's Why Ocugen Shares Are Falling
Ocugen Inc (NASDAQ: OCGN) shares are trading lower by 5.86% to $2.73 during Tuesday's pre-market session after the company announced that it was informed by the FDA that... 
Via Benzinga
Earnings Scheduled For May 6, 2022
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion. 
Via Benzinga
What the WHO Snub Means For Ocugen Stock Investors?
Add the World Health Organization's suspension of Covaxin to the list of troubles that are weighing down OCGN stock. 
Via InvestorPlace
Why Is Ocugen (OCGN) Stock Up 10% Today?
Sometimes, improved investor sentiment and a revamped website is enough of a catalyst to take something like OCGN stock on a 10% ride higher. 
Via InvestorPlace
Novavax Stock Could Give Back More of Its Pandemic-Era Gains
While trading at a very low multiple to the low end of earnings estimates, NVAX stock may still be trading at a premium. 
Via InvestorPlace
State Street Just Bought Ocugen (OCGN) Stock. Here’s Why.
OCGN stock has declined by over 90% in the past five years. However, that hasn't stopped State Street from more than doubling its position. 
Via InvestorPlace
Why Is Lixte Biotechnology (LIXT) Stock Up Today?
Lixte Biotechnology (LIXT) stock is rocketing higher on Tuesday after the company revealed pre-clinical results for one of its treatments. 
Via InvestorPlace
Read Why Did WHO Suspend UN Supply of Bharat Biotech's Covaxin COVID-19 Vaccine
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
If you're looking for the biggest pre-market stock movers for Monday, we've got you covered with a list of gainers and losers for today. 
Via InvestorPlace
26 Stocks Moving in Monday's Pre-Market Session
Gainers SPI Energy Co., Ltd. (NASDAQ: SPI) rose 36.3% to $3.87 in pre-market trading after reporting record revenue of $162 million for 2021. Twitter, Inc. (NYSE: TWTR) rose... 
Via Benzinga
These Were The 20 Most Searched Tickers On Benzinga In The First Quarter: Did Your Favorite Stock Make The List?
The first three months of 2022 are in the books, bringing the first quarter to a close. Investors were faced with many macro events, including rising inflation and the war in Ukraine. Benzinga was a... 
Via Benzinga
It’s Time to Get Clinical, Not Cynical, With Ocugen Stock
The selling pressure on OCGN stock has been as heavy as a rock, but worried shareholders should celebrate Ocugen's breakthrough moments. 
Via InvestorPlace
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.